US biotech Merida Biosciences has launched with $121m in Series A financing to develop therapeutics targeting disease-causing ...

These findings provide mechanistic evidence linking neonatal antibiotic exposure to impaired vaccine immunogenicity via ...

Inebilizumab (Uplizna) improved function and reduced disease severity for up to 52 weeks in generalized myasthenia gravis ...

ADCs consist of three modifiable primary components: the antibody backbone, the cytotoxic payload and the linker that joins the two. The drug linker is typically created as a peptide or ...

The company’s antibody–drug conjugate (ADC ... a modular engineering approach to improve the performance of key ADC components, such as conjugation chemistry, linker stability and ...

Experts discuss why it is critical to have standardized protocols in place for managing cytokine release syndrome (CRS) in patients receiving bispecific antibodies, outlining the key components of an ...

Long-lasting in vivo antibody production: DMAb levels remained stable for 72 weeks in all participants (n=24) who have reached that timepoint No anti-drug antibodies (ADA): no immune rejection of ...

Researchers have found that the absence of this antibody leads to an overgrowth ... that the abnormally increased IgG response to components of the gut microbiota and impaired response to vaccines ...